Slide 1: TPIP Phase 2 PH-ILD Topline Results & Phase 2 PAH Blended Blinded Data Update
May 2024 TPIP Phase 2 PH-ILD Topline Results & Phase 2 PAH Blended Blinded Data Update
Slide 2: Forward-Looking Statements
Forward Looking Statement Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not hist
Slide 3: TPIP Phase 2 PH-ILD Study Design & Endpoints
TPIP Phase 2 PH-ILD Study Design & Endpoints 4 weeks TPIP 80-640 µg inhalation capsules QD Placebo inhalation capsules QD Screening Treatment period 16 weeks Baseline EOT (primary analysis) EOS 4 weeks Primary Endpoints Secondary Endpoints 3 Follow-up Pharmacokinetics 39 participants randomized in t
Slide 4: Demographics and Baseline Characteristics
Characteristics TPIP QD(N=29) Placebo(N=10) Age, mean (SD) Age (years) 65.7 (7.65) 63.8 (10.55) Sex, % (n) Male 69.0 (20) 80.0 (8) Female 31.0 (9) 20.0 (2) Ethnicity, % (n) Hispanic or Latino 24.1 (7) 20.0 (2) Race, % (n) White 82.8 (24) 90.0 (9) Multiple/ Not Reported 17.2 (5) 10.0 (1) BMI, mean (S
Slide 5: PH-ILD Phase 2 Study Met Primary Objective of Safety and Tolerability
PH-ILD Phase 2 Study Met Primary Objective of Safety and Tolerability, With Lower Rates of Treatment Discontinuation and SAEs Compared to Placebo TPIP (N=29) Placebo (N=10) Dose Titration % Patients Titrated to Maximum 640 µg Dose of TPIP or Placebo (n) % Patients Titrated to at least 480 µg Dose of
Slide 6: No Meaningful Changes in Oxygen Saturation Levels Compared to Baseline for Patients Treated with TPIP
TPIP QD (N=29) Placebo (N=10) n Change from Baseline to Week 16 n Change from Baseline to Week 16 Supplemental Oxygen Use (L/min) 24 0.0 (0.91) 8 0.6 (2.20) Pre-6MWT SpO2 (%) 24 -0.3 (5.64) 8 -0.9 (3.04) Lowest SpO2 (%) 22 -4.6 (11.65) 8 -1.3 (7.03) Post-6MWT SpO2 (%) 23 -8.2 (14.07) 8 1.1 (4.45) 6
Slide 7: Phase 2 PH-ILD Exploratory Efficacy Endpoints Support Advancement into Phase 3
Phase 2 PH-ILD Exploratory Efficacy Endpoints Support Advancement into Phase 3 TPIP (N=29) Placebo (N=10) Week 16 n Week 16 n 6-Minute Walk Distance (6MWD) Treatment effect (TPIP vs. placebo) at Week 161 (m) Confidence interval P-value 30 [-49.0, 171.0] 0.3484 29 N/A 10 NT-proBNP concentrations (pg/
Slide 8: Blended Blinded Phase 2 Data in PAH Indicates Potential of TPIP to Become Best-in-Class Prostanoid
Blended Blinded Phase 2 Data in PAH Indicates Potential of TPIP to Become Best-in-Class Prostanoid Blended/Blinded Data from Treatment and Placebo Arms (2:1 Randomization) Dose Titration1 Patients Titrated to Maximum Dose of 640 µg or Placebo (%) 34 (79%) of first 43 patients who reached Week 5 visi